Abstract Deadline Abstracts will be accepted on or before 28th June 2012. Abstracts must be submitted via email (firstname.lastname@example.org).
All authors are encouraged to carefully review the guidelines for abstract submission both in terms of content and format. How to Prepare Your Paper: Abstract Content The abstract of the work proposed to be presented should be typed according to the instructions given below and submitted through E-mail on or before 28th June 2012. The abstracts should be typed only in the prescribed format. The following sections are REQUIRED and should be IN THIS ORDER. A) TITLE: Type the complete title of abstract in the Times New Roman using font size of 12 and in bold B) AUTHORS AND CO-AUTHORS: Names of authors and address/es should be written below the title in the Times New Roman, using font size of 12. The presenting author name must be underlined, This person is expected to present the paper. If emergencies at the time of the conference prohibit the participation of this designated author, the chair(s) of the conference must be notified as soon as possible. (Maximum author should not be more than 4) Type author(s) name(s) and institution with city, state, country and code. List email address of presenting author. Do not use titles; i.e. Dr., Ph.D., etc. Only affiliation of presentaing author should be mentioned, Do not mention affiliations of co-authors. C) ABSTRACT: Abstract should also be submitted in MS World Version 6.0/95 or a higher version. The text of the abstract should be typed in Times New Roman using font size of 12 with title in bold. The abstract should not be more than 250 words.
Model Abstract Triacetin based self emulsifying formulation of a poorly water soluble drug
Pharmaceutical Division, University Institute of Chemical Technology,
Nathalal Parikh Marg, Matunga, Mumbai- 400019, India.
The present study deals with formulation of a Triacetin based Self emulsifying formulation of a poorly water soluble drug. Triacetin (Glyceryl Triacetate) is a water miscible solvent with high capacity for solubilizing lipophilic agents. This property of triacetin makes it an interesting excipient to work with especially in case of self emulsifying formulations as it can serve a dual purpose of co-solvency as well as an emulsification aid. The present research work describes a Self Emulsifying Formulation (SEF) of furosemide using triacetin as a co-solvent. Furosemide is a high loop diuretic with limited water solubility, which accounts for a low and variable oral bioavailability (20%-60%). Hence, the main objective of study was to formulate SEF of furosemide in order to achieve a better dissolution rate which would further help in enhancing oral bioavailability. Pseudo-ternary phase diagrams were plotted to check for the micro-emulsification range and also to evaluate the effect of triacetin on the emulsification behavior of the phases. The mixtures consisting of Maisine or Labrafac hydro (HLB value > 4) with surfactant (Tween 80), co-surfactant (PEG 400) and co-solvent (Triacetin) were found to be optimum formulations. Increasing triacetin concentration in the formulation resulted in a wider micro-emulsion existence field as compared to combinations containing no or lower amounts of triacetin. Particle size of the developed formulation was found to be (<100nm) with poly dispersibility index of 0.0876. Freeze thaw cycling and centrifugation studies were carried out to confirm the stability of the formed SEF. The formulation was found to show a significant improvement in terms of the drug release with complete release of drug within 15 minutes. Thus, Self microemulsifying formulation of furosemide was successfully developed.
1. The area provided for poster presentation will not be more than 1 meter wide by 1meter
2. The title of the poster should cover the full width of the poster. The title should be brief,
informative and written in bold letters. The names of authors address/es should be written
below the title in small letters. The name of the presenting author should be underlined.
3. The sizes of the letter should be such that a viewer can read it from 2 meter distance. The
message should be clear and understandable without oral explanation.
C H A P T E R e 2 6 Amodiaquine Amodiaquine has been widely used in the treatment of malaria for >40 years. Like chloroquine (the other major 4-aminoquinoline), amodiaquine is now of limited use because of the spread of resis-tance. Amodiaquine interferes with hemozoin formation through complexation with heme. Although rapidly absorbed, amodiaquine behaves as a prodrug after oral
April 2, 2008 NCAA Committee on Competitive Safeguards and Medical Aspects of Sports -- Medical Exceptions and Banned Drug Classes. The NCAA Committee on Competitive Safeguards and Medical Aspects of Sports in conjunction with the NCAA Health and Safety staff has issued the following educational article on medical exceptions and banned drug classes. Please contact Mary Wilfert, associate di